13 Best Psychedelic Stocks to Invest in Now

Page 4 of 11

8. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Number of Hedge Fund Holders: 12 

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company developing neuroscience-focused therapies, including innovative intranasal pherine compounds. Its lead candidate, fasedienol, targets social anxiety disorder (SAD), with Phase 3 PALISADE-3 trial results expected in Q4 2025, a milestone that could be pivotal for the company. The business is also advancing other candidates, such as PH80 for menopausal hot flashes and itruvone for major depressive disorder, reflecting a diversified neuropsychiatric pipeline.

Recent efforts have focused on enhancing trial quality, regulatory communication, and research collaborations. Financially, the corporation remains strong with around $63 million in cash equivalents as of June 2025, supporting ongoing R&D initiatives. The mid-2025 appointment of a Chief Corporate Development Officer signals a strategic push toward business development and partnership expansion.

The upcoming PALISADE-3 readout is a key event for investors, given the substantial unmet need in SAD. Follow-up data from PALISADE-4 is also expected in the first half of 2026, indicating continued pipeline momentum. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)’s emphasis on intranasal pherine compounds highlights a novel mechanism of action in treating neuropsychiatric conditions, setting it apart in a competitive landscape.

While the company faced operational challenges, including a trial site closure in Pennsylvania due to recruitment issues, overall clinical progress remains on track. Market sentiment shows rising technical momentum, though outcomes and competition present inherent risks.

Page 4 of 11